Working within community and hospital settings, Exon Consultancy has evaluated systems and practices in the Dutch hospital setting for tracking biological product information and processes for reporting adverse drug reactions. Additional analyses were performed by Utrecht University to estimate the potential impact of exposure misclassification during ADR reporting on safety signal detection for biologics. Results were presented in a number of journal publications presenting valuable new insights into the ADR reporting processes of biologics.
More information about the project can be found here.